Gibson, David and Jordan, Grant (2012) AN INVESTIGATION INTO THE USE OF HUMAN BONE MARROW OSTEOGENIC CELLS IN THE TREATMENT OF BONE DEFECTS. In: British Orthopaedic Research Society (BORS), Cardiff, Wales, 12 - 13 July 2010. BRITISH EDITORIAL SOCIETY OF BONE AND JOINT SURGERY. 2 pp. [Conference contribution]
Full text not available from this repository.
Introduction Problematic bone defects are encountered regularly in orthopaedic practice particularly in fracture non-union, revision hip and knee arthroplasty, following bone tumour excision and in spinal fusion surgery. At present the optimal source of graft to ‘fill’ these defects is autologous bone but this has significant drawbacks including harvest site morbidity and limited quantities. Bone marrow has been proposed as the main source of osteogenic stem cells for the tissue-engineered cell therapy approach to bone defect management. Such cells constitute a minute proportion of the total marrow cell population and their isolation and expansion is a time consuming and expensive strategy. In this study we investigated human bone marrow stem cells as a potential treatment of bone defect by looking at variability in patient osteogenic cell populations as a function of patient differences. We produced a model to predict which patients would be more suited to cell based therapies and propose possible methods for improving the quality of grafts. Methods Bone marrow was harvested from 30 patients undergoing elective total hip replacement surgery in Musgrave Park Hospital, Belfast (12 males, 18 females, age range 52-82 years). The osteogenic stem cell fraction was cultured and subsequently analysed using colony forming efficiency assays, flow cytometry, fluorescence activated cell sorting and proteomics. Results The number and proliferative capacity of osteogenic stem cells varied markedly between patients. Statistical analysis revealed significantly better osteogenic capacity in: •male patients•samples in which the growth hormone Fibroblastic Growth Factor-2 was added to culture medium•patients who used the cholesterol lowering agent simvastatinPatient use of inhaled steroids and NSAIDs were found to have detrimental effects. A statistical model to predict marrow profiles based on these variables was produced. Conclusions Stem cell based tissue engineering represents the future of the treatment of bone defect. This study provides evidence that inter-patient variability in marrow cell colony forming and proliferation ability can in some way be explained by patient associated factors. Using this knowledge, we can identify which patients would be best suited to this method of treatment and propose techniques for enhancement of their graft profiles.
|Item Type:||Conference contribution (Poster)|
|Faculties and Schools:||Faculty of Life and Health Sciences > School of Biomedical Sciences|
Faculty of Life and Health Sciences
|Research Institutes and Groups:||Biomedical Sciences Research Institute|
Biomedical Sciences Research Institute > Stratified Medicine
|Deposited By:||Dr David Gibson|
|Deposited On:||30 Nov 2012 13:53|
|Last Modified:||15 Oct 2013 14:54|
Available Versions of this Item
- AN INVESTIGATION INTO THE USE OF HUMAN BONE MARROW OSTEOGENIC CELLS IN THE TREATMENT OF BONE DEFECTS. (deposited 30 Nov 2012 13:53) [Currently Displayed]
Repository Staff Only: item control page